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Abstract
Background:  Knock-in mice (gp130F759) with a Y759F point mutation in gp130, a signal
transducing receptor subunit shared by members of the IL-6 cytokine family, show sustained
activation of STAT3, enhanced acute-phase or immune responses, and autoimmune arthritis. We
conducted a detailed analysis of collagen-induced arthritis (CIA) in gp130F759 with a DBA/1J
background (D/J.gp130F759).
Methods: We backcrossed gp130F759 to C57BL/6 and DBA/1J, and compared the pathologic
changes, including occurrence of arthritis, in the two distinct genetic backgrounds. We analyzed
CIA in D/J.gp130F759 and investigated the effects of methotrexate (MTX) on CIA.
Results: C57BL/6 background gp130F759 mice, but not D/J.gp130F759, spontaneously developed
polyarthritis and glomerulonephritis. On the other hand, keratitis of the eyes only developed in D/
J.gp130F759, indicating the influence of genetic background on disease development in gp130F759
mice. Resistance of the DBA/1J background against spontaneous arthritis urged us to examine CIA
in D/J.gp130F759. CIA in D/J.gp130F759 was more severe, with greater bone destruction, than the
control mice. After collagen immunization, splenomegaly and serum levels of rheumatoid factor and
anti-DNA antibody were augmented in D/J.gp130F759. Bio-Plex analysis of serum cytokines
revealed increased IL-12p40 and PDGF-BB before immunization, and increased levels of IFN-γ, IL-
17, TNF-α, IL-9, and MIP-1β 8 days after the booster dose. IL-6 and PDGF-BB in D/J.gp130F759
showed distinct kinetics from the other cytokines; higher levels were observed after arthritis
development. MTX partially attenuated the development of arthritis and inhibited bone destruction
in D/J.gp130F759, with reduction of anti-type II collagen antibody levels, suggesting that MTX
mainly affects antigen-specific immune responses in CIA.
Conclusion: The Tyr-759 point mutation of the IL-6 family cytokine receptor subunit, gp130,
caused autoimmune disease, and this was also influenced by the genetic background. CIA in D/
J.gp130F759 is useful for evaluating drugs in a relatively short period because sustained activation
of STAT3 may enhance the disease symptoms.
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Background
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease characterized by progressive chronic inflammation of
multiple joints, resulting in joint destruction. Several
characteristics of RA, such as hyper-γ-globulinemia,
autoantibody production, genetic linkage with the HLA-
DR locus, and infiltration of T-cells and plasma cells into
the synovium, have suggested that immunologic disor-
ders have crucial roles in the pathogenesis of this disease
[1]. RA is a polygenic disease caused by immunologic dis-
orders that develop from the synergistic actions of genetic
and environmental factors. Clinical and experimental
studies have revealed the pivotal roles for inflammatory
cytokines, such as tumor necrosis factor (TNF)-α, inter-
leukin (IL)-1, and IL-6, in the pathophysiology of RA [2].
Success achieved in the blockade of TNF-α in RA and IL-6
in juvenile RA exemplifies the feasibility and potential
therapeutic application of antagonizing cytokine signal-
ing [3].
IL-6 is a pleiotropic cytokine that regulates various bio-
logic functions, such as the development of the nervous
and hematopoietic systems, acute-phase responses,
inflammation, and immune responses [4]. A causative
role for IL-6 in autoimmune disease was first recognized
by the observation that the autoimmune symptoms of
patients with cardiac myxomas, such as hyper-γ-glob-
ulinemia and autoantibody production, disappeared with
resection of the tumor that produced IL-6 [5]. Further-
more, a high concentration of IL-6 exists in the synovial
fluid and sera of RA patients [6]. Studies using IL-6 knock-
out mice revealed that IL-6 is involved in the severity and
progress of experimentally-induced arthritis [7-9]. Clini-
cal trials of a humanized anti-IL-6Rα monoclonal anti-
body (MRA) have provided evidence supporting the
crucial roles for IL-6 in RA pathophysiology [3].
The IL-6 receptor comprises two molecules, IL-6 receptor
α-chain and gp130, which is shared among the receptors
for the IL-6 cytokine family. Ligand binding of gp130 acti-
vates two major signal-transduction pathways (the STAT3-
mediated signal and the SHP-2/Gab/MAPK signal) in a
manner dependent on the YXXQ motif and tyrosine (Y)
759 of gp130, respectively [10,11].
To clarify the roles of SHP-2- and STAT3-mediated signal-
transduction pathways in vivo, we generated a series of
knock-in mouse lines in which the gp130-mediated
STAT3 or SHP-2 signals were selectively disrupted. This
was achieved by mutating the tyrosine residues of all the
YXXQ motifs or Y759 to phenylalanine (gp130FXXQ/FXXQ
and gp130F759/F759 mice, respectively [the latter is hereafter
abbreviated gp130F759]). Analyses of these mice indi-
cated that SHP-2-mediated or Y759-dependent signals
negatively regulate the biological responses elicited by the
STAT3-mediated signals in vivo, and that the balance of
positive and negative signals generated through gp130 is
skewed or shifted to positive STAT3 signaling in
gp130F759 [12]. Importantly, gp130F759 in the mixed
background with 129 and C57BL/6 spontaneously
develop a RA-like autoimmune disease in old age [13].
gp130F759 shows severe immunologic abnormalities,
including autoantibody production, increased memory/
activated T-cells, impaired thymic negative selection, and
peripheral clonal deletion. Development of RA-like dis-
ease is entirely dependent on mature lymphocytes, but
abnormally enhanced homeostatic proliferation of CD4
T-cells is caused by augmented production of IL-7 by non-
hematopoietic stromal cells through a STAT3-dependent
process [14]. However, the 129/C57BL/6 mixed back-
ground gp130F759 mice were not suitable for drug evalu-
ation due to the late onset (approximately 1 year). We,
therefore, backcrossed gp130F759 to DBA/1J, which is
known to develop arthritis by immunization of heterolo-
gous type II collagen, with the expectation of an earlier
development of spontaneous arthritis.
Here, we report the histopathologic abnormalities in two
genetic backgrounds of gp130F759, and analyze collagen-
induced arthritis (CIA) in gp130F759 with a DBA/1J back-
ground for the development of a model for drug evalua-
tion.
Methods
Animals
Experimental procedures were conducted with the
approval of the Santen Animal Experimental Ethics Com-
mittee.
gp130F759/F759 knock-in mice were backcrossed to C57BL/
6 or DBA/1J eight times (Japan SLC Inc., Hamamatsu,
Japan), hereafter abbreviated B6.gp130F759 and D/
J.gp130F759, respectively. In all studies, we used wild-
type mice (Japan SLC Inc.) as controls. Mice were housed
in a specific pathogen-free animal facility at the Research
and Development Center of Santen Pharmaceutical Com-
pany Limited. A 12-h light/dark cycle was maintained in a
room at 23 ± 1°C. Mice had free access to food and water.
Organ analysis
Mice were sacrificed at 12 months for the comparative
study of mice with two genetic backgrounds. Eyes, limbs,
spleen, thymus, mesenteric lymph nodes, lungs, and kid-
neys were histologically-examined. The weights of the
spleen and thymus were recorded. For the study of CIA,
mice were sacrificed at the end of the experimental period
(day 56) by exsanguination. After measuring the weights
of the spleen and thymus, the organs were fixed in 10%
neutral buffered formalin solution. After fixation, the
joints were decalcified in 10% ethylenediaminetetraace-BMC Musculoskeletal Disorders 2009, 10:23 http://www.biomedcentral.com/1471-2474/10/23
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tate solution for 3 weeks. Paraffin-embedded samples
were sectioned and stained with hematoxylin and eosin.
Sections were examined under light microscopy.
CIA
CIA was induced in D/J.gp130F759 and wild-type mice
according to the method described previously [15]. We
previously reported that arthritis in D/J.gp130F759 mice
was more severe than in control mice when the interval
immunization of bovine type II collagen was 3 weeks
[16]. In this study, we chose an interval immunization
protocol of 2 weeks to develop arthritis in a shorter
period. Mice were injected intradermally into the base of
the tail with 200 μg of bovine type II collagen emulsified
in Freund's complete adjuvant (FCA). Two weeks after the
initial injection, a booster injection of 200 μg of bovine
type II collagen emulsified in FCA was administered intra-
dermally into the base of the tail. The activity of clinical
arthritis was evaluated twice a week from the first immu-
nization (day 0) until day 56. The severity of clinical
arthritis in the limbs was scored as 0 (no arthritis), 1
(swelling of one digit), 2 (swelling of two or more digits),
3 (swelling of the paw), and 4 (swelling of the paw and
changes in the bone). The arthritic score was the sum of
the scores of all involved joints. The joints were processed
for histologic analysis at the end of the experimental
period (56 days). Proliferation of synovial cells, joint
destruction, and lymphocyte infiltration into the synovial
lining were blindly evaluated. The histopathologic scores
of the hind paw were graded on the basis of the changes
to the intact joints, as described previously [17]: 0 (nega-
tive), 1 (very slight: slight change in a few joints, no
change in many joints), 2 (slight: moderate change in few
joints, no change or slight change in many joints), 3
(moderate: severe or moderate change in many joints,
slight change in a few joints), and 4 (severe: severe change
in every joint).
For drug evaluations, methotrexate (MTX; Sigma, St.
Louis, MO, USA) at 0.2 mg/kg was administered p.o. once
daily from the first immunization until day 42, and the
activity of clinical arthritis was evaluated. At the end of the
experimental period (42 days), the joints were processed
for histologic examination. Proliferation of synovial cells,
joint destruction, and lymphocyte infiltration into the
synovial lining were blindly evaluated.
IL-2 production in lymph node cells
Mice were sacrificed 14 days after the first immunization.
The inguinal lymph nodes were removed, and single-cell
suspensions were prepared in complete medium
(RPMI1640 supplemented with 1% autologous mouse
serum, 5 × 10-5 M 2-mercaptoethanol, 100 units/mL pen-
icillin, and 100 μg/mL streptomycin). Lymph node cells
(4 × 106 cells/mL) with 200 μL of complete medium were
cultured in the presence or absence of 5 μg/mL of bovine
type II collagen or 1 μg/mL of concanavalin-A for 2 days.
Thereafter, supernatants were collected for measurement
of IL-2 production.
Detection of cytokines, autoantibodies, and cartilage 
oligomeric matrix protein (COMP)
Serum cytokines were measured using the Bio-Plex sus-
pension array system (Biorad, Hercules, CA, USA). Mouse
IL-7, rheumatoid factor (RF) for mouse immunoglobulin
(Ig) of IgM classes, and anti-ssDNA antibodies were meas-
ured using a commercial ELISA kit (R&D Systems, Minne-
apolis, MN, USA; Shibayagi, Gunma, Japan). Levels of
anti-type II collagen antibody were measured by ELISA
using a mouse IgG anti-type II collagen antibody assay kit
(Chondrex, Redmond, WA, USA). COMP levels were
measured using a commercial ELISA kit (AnaMar Medical,
Göteborg, Sweden).
Statistical analyses
Results were evaluated by Student's t-test (EXSAS; Arm,
Osaka, Japan).
Results
Abnormalities in gp130F759 knock-in mice with distinct 
genetic backgrounds
Abnormalities in gp130F759 mice with the C57BL/6 or
DBA/1J background are shown in Tables 1 &2. The char-
acteristic abnormalities of B6.gp130F759 mice in both
sexes were polyarthritis and hyperplasia of the spleen and
lymph node. Glomerulonephritis only developed in
females. These abnormalities were not observed in the
DBA/1J background. D/J.gp130F759 mice were resistant
to spontaneous polyarthritis, even though DBA/1J-back-
ground mice were known to develop CIA. Cellular infiltra-
tion in the lung and hypertrophy of the thymus were
observed in both backgrounds. On the other hand, kerati-
tis developed with a much higher prevalence in the DBA/
1J background. These results indicated that the pathologic
changes caused by the Y759F point mutation of gp130
were affected by the genetic background of the mice.
CIA in DBA/1J background gp130F759 mice
We attempted to induce CIA in DBA/1J background
knock-in mice to determine if the point mutation affected
the prevalence or course of CIA because D/J.gp130F759
mice did not develop spontaneous arthritis up to 4
months of observation (data not shown). The severity of
polyarthritis in D/J.gp130F759 mice was higher than that
in wild-type mice (Fig. 1). The prevalence of polyarthritis
at day 56 was 100% in D/J.gp130F759 and wild-type
mice. The degree of arthritis in gp130F759 mice was more
severe in the hind limbs than in the forelimbs. Therefore,
we examined the histologic changes in the hind limbs,
such as proliferation of the synovial cells, joint destruc-BMC Musculoskeletal Disorders 2009, 10:23 http://www.biomedcentral.com/1471-2474/10/23
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tion, and lymphocyte infiltration into the synovial lining
(Table 3). The histologic analysis showed that the severity
of arthritis was greater with high bone destruction in
gp130F759 mice than in wild-type mice. The histopatho-
logic grades of gp130F759 mice tended to converge at 2 or
3, whereas those of wild-type mice diverged from 0–4.
Before immunization, spleen weights in D/J.gp130F759
mice were approximately 1.3-times higher than the con-
trol mice. After immunization, the weights increased
approximately 1.8-times compared to the controls (Fig.
2). Before immunization, the serum level of RF was a little
higher in gp130F759 mice with little differences between
males and females, which did not change significantly by
collagen immunization (Fig. 3). The serum level of anti-
ssDNA antibody was higher in gp130F759 mice before
and after immunization (Fig. 4). The level of anti-type II
collagen antibody, which was scarcely detected before
immunization, was lower in gp130F759 mice, even after
immunization, with little differences between males and
females (Fig. 5).
Bio-Plex analysis of serum cytokines revealed that non-
stimulated female D/J.gp130F759 mice showed signifi-
cantly increased levels of IL-12(p40) and platelet-derived
growth factor-BB (PDGF-BB; Fig. 6). On day 22, 8 days
after the second immunization, the serum levels of TNF-
α, interferon (IFN)-γ, IL-17, IL-9, and macrophage inflam-
matory protein (MIP)-1β were significantly higher in
female D/J.gp130F759 mice, all of which returned to
basal levels comparable with those of wild-type mice on
day 56. Levels of IL-6 and PDGF-BB on day 56 further
Table 1: Histopathological analysis of gp130F759 mice (12 months) Male
C57BL/6 DBA/1J
Findings Wild F759 Wild F759
Joint (lower extremity); Synovial cell proliferation 0/5 5/5 0/5 0/5
Kidney; Glomerulonephritis 0/5 0/5 0/5 0/5
Eye; Keratitis 0/5 0/5 1/5 4/5
Lung; Cellular infiltration 0/5 5/5 0/5 3/5
Spleen; Hyperplasia, plasma cell 0/5 5/5 0/5 0/5
Thymus; Hypertrophy/hyperplasia, medulla 0/5 5/5 0/5 2/5
Lymph node (mesenteric); Hyperplasia, plasma cell 0/5 4/5 0/5 0/5
Table 2: Histopathological analysis of gp130F759 mice (12 months) Female
C57BL/6 DBA/1J
Findings Wild F759 Wild F759
Joint (lower extremity); Synovial cell proliferation 0/5 5/5 2/5 0/5
Kidney; Glomerulonephritis 0/5 2/5 0/5 0/5
Eye; Keratitis 0/5 1/5 0/5 3/5
Lung; Cellular infiltration 3/5 3/5 1/5 1/5
Spleen; Hyperplasia, plasma cell 0/5 5/5 0/5 0/5
Thymus; Hypertrophy/hyperplasia, medulla 0/5 5/5 0/5 4/5
Lymph node (mesenteric); Hyperplasia, plasma cell 2/5 5/5 0/5 0/5BMC Musculoskeletal Disorders 2009, 10:23 http://www.biomedcentral.com/1471-2474/10/23
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increased in female D/J.gp130F759 mice, whereas levels
declined or were unchanged in wild-type mice. Serum IL-
7 was not detectable in CIA mice by ELISA (sensitivity, 10
pg/mL). On days 0 and 56, cytokine data in male and
female mice were almost identical (data not shown). We
did not conduct the cytokine analysis of male serum on
day 22.
IL-2 production in lymph node cells
IL-2 production in lymph node cells of female D/
J.gp130F759 mice stimulated by collagen and concanava-
lin-A was slightly higher than in control mice (Fig. 7). In
addition, spontaneous IL-2 production in lymph node
cells of D/J.gp130F759 mice was also slightly higher than
in the control mice. Lymphocyte proliferation in
gp130F759 mice and the control mice was similar in both
backgrounds (data not shown). These results suggest that
Table 3: Destructive arthritis developed in CIA in DBA/1J gp130F759 mice
Day 56 Male Female
Wlid F759 Wild F759
Grade 20* 16* 20* 14*
Proliferation of the synovial lining cells 0 7 0 8 1
1 1140
2 3321
3 71 041 1
4 2221
Destruction of the articular cartilage/bone 0 9 3 14 1
1 0010
2 4020
37 8 2 1 3
4 0510
Inflammatory cell infiltration, rich in neutrophils 0 10 3 12 1
1 1021
21 1 1 2 6
3 5235
4 3011
All data refer to the number of limbs with the finding in the group.
*Total number of limbs in the group
Grade of change: 0, negative; 1, very slight; 2, slight; 3, moderate; 4, severe.
Severe arthritis developed in gp130F759 mice by collagen  immunization Figure 1
Severe arthritis developed in gp130F759 mice by col-
lagen immunization. D/J.gp130F759 and wild-type mice 
were injected intradermally with collagen emulsified in FCA 
on day 0 and day 14. Values are expressed as mean ± stand-
ard error of 7 to 10 animals. *P < 0.05, **P < 0.01 versus 
wild-type mice by Student's t-test.
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Marked splenomegaly in CIA of D/J.gp130F759 mice Figure 2
Marked splenomegaly in CIA of D/J.gp130F759 mice. 
Values are expressed as mean ± standard error of 7 to 10 
animals of collagen-immunized mice on day 56 (a) and 3 to 4 
animals of non-immunized mice (b). *P < 0.05, **P < 0.01 ver-
sus wild-type mice by Student's t-test.
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the Y759F mutation of gp130 scarcely affected T-cell
immune responses in CIA.
Effects of MTX on CIA in DBA/1J background gp130F759/
F759 knock-in mice
We investigated the effects of MTX on CIA in DBA/1J back-
ground male gp130F759 mice to determine if this model
would be useful for drug evaluation. Severe polyarthritis
was observed in the vehicle-treated group, but MTX (0.2
mg/kg/day) partially attenuated it (Fig. 8a). MTX also
delayed the onset of polyarthritis (Fig. 8b). Histologic
analysis showed that severe arthritis with high bone
destruction was observed in the vehicle-treated group,
which was inhibited by MTX (Table 4). The COMP data
also supported these findings in the histopathologic anal-
ysis. The increased serum level of COMP in the vehicle-
treated group at the end of the experimental period was
nearly suppressed by treatment with MTX (Fig. 9a). MTX
Increased serum levels of rheumatoid factor in CIA of D/ J.gp130F759 mice Figure 3
Increased serum levels of rheumatoid factor in CIA 
of D/J.gp130F759 mice. Values are expressed as mean ± 
standard error of 7 to 10 animals of collagen-immunized 
mice on day 56 (a) and 3 to 4 animals of non-immunized mice 
(b). *P < 0.05, **P < 0.01 versus wild-type mice by Student's 
t-test.
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Increased serum levels of anti-ssDNA antibody in CIA of D/ J.gp130F759 mice Figure 4
Increased serum levels of anti-ssDNA antibody in 
CIA of D/J.gp130F759 mice. Values are expressed as 
mean ± standard error of 7 to 10 animals of collagen-immu-
nized mice on day 56 (a) and 3 to 4 animals of non-immu-
nized mice (b). *P < 0.05, **P < 0.01 versus wild-type mice by 
Student's t-test.
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Serum levels of anti-collagen antibody in CIA of D/ J.gp130F759 mice on day 56 Figure 5
Serum levels of anti-collagen antibody in CIA of D/
J.gp130F759 mice on day 56. Values are expressed as 
mean ± standard error of 7 to 10 animals on day 56. *P < 
0.05 versus wild-type mice by Student's t-test.
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Serum cytokines that showed different responses in D/ J.gp130F759 mice (female) Figure 6
Serum cytokines that showed different responses in 
D/J.gp130F759 mice (female). Serum cytokine levels 
were measured by Bio-Plex system. Values are expressed as 
mean ± standard error of 7 to 10 animals. *P < 0.05, **P < 
0.01 versus wild-type mice at same day by Student's t-test.
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also attenuated the anti-type II collagen antibody level,
which was increased by collagen immunization (Fig. 9b).
Despite histologic improvement, MTX scarcely affected
the serum level of anti-ssDNA antibody, RF, MIP-1β, TNF-
α, IL-6, IL-9, IL-17, and IFN-γ at the end of the experimen-
tal period (data not shown).
Discussion
Many abnormalities were shown in B6.gp130F759 mice
at 12 months of age. Characteristic abnormalities in
C57BL/6 background knock-in mice were not only spon-
taneous polyarthritis, but also glomerulonephritis (only
in females). Spontaneous arthritis did not develop in the
DBA/1J background, indicating that the genetic back-
ground of DBA/1J is resistant to spontaneous arthritis
caused by the Y759F mutation of gp130. On the other
hand, keratitis was characteristic in D/J.gp130F759 mice.
These different abnormalities between mice with two
backgrounds may have been caused by differences in their
H-2 haplotype (C57BL/6; b, DBA/1J; q). Thymic hyper-
plasia was observed in both backgrounds, but splenic
hyperplasia only occurred in the C57BL/6 background.
This abnormality may be an important requisite for the
development of spontaneous arthritis.
We tried to induce CIA in DBA/1J background knock-in
mice resistant to spontaneous polyarthritis. The severity of
polyarthritis in gp130F759 mice was greater in wild-type
mice when the 2-week interval immunization protocol
was followed, which was similar to our previous study
results involving a 3-week interval immunization proto-
col [16]. In the 2-week interval immunization protocol,
the development of arthritis was observed more rapidly
than in the 3-week interval immunization protocol. To
achieve a score of 10, it takes almost 50 days from the first
immunization by the 3-week interval immunization pro-
tocol [16], but it takes only 40 days by the 2-week interval
immunization protocol. The severity of arthritis in
gp130F759 mice was greater than in the control mice.
From cytokine analysis, the high level of IL-6 in serum was
maintained in gp130F759 mice after the second immuni-
zation. Serum levels of IL-6 are also correlated with clini-
cal indices of disease activity in RA [18], and high levels of
IL-6 may trigger a positive-feedback loop of gp130 signal-
ing. Serum levels of PDGF-BB, one of the angiogenesis fac-
tors produced mainly by macrophages, was also elevated.
It has been reported that PDGF and the PDGF receptor are
overexpressed in RA synovial tissue, and PDGF is a potent
stimulator of synovial hyperplasia in RA [19-21]. The
tyrosine kinase inhibitor, imatinib, attenuates PDGF
receptor signaling in fibroblast-like synoviocytes, and
potently prevents and treats murine CIA [22]. PDGF-BB
induces IL-6 production in osteoblasts [23]. These find-
ings suggest that a high level of PDGF-BB in the serum of
gp130F759 mice may be involved in angiogenesis and
synovial hyperplasia. Further studies to clarify the mecha-
nisms for sustained elevation of IL-6 and PDGF-BB need
to be conducted in the future.
In gp130F759 mice with CIA, the serum levels of TNF-α,
IL-9, IL-17, IFN-γ, and MIP-1β were elevated 8 days after
the second immunization. TNF-α has an important role in
RA [2], particularly growth of synovial fibroblasts. IFN-γ
has long been known to be a critical T-helper (Th)1
cytokine in the initiation and perpetuation of inflamma-
tion and autoimmune disease [24]. It has been reported
that anti-IFN-γ-treated RA patients demonstrate signifi-
cant clinical improvement [25]. IL-9 is considered to a
Th2 cytokine, and has been shown to act on many cell
types, including T cells, B cells, mast cells, eosinophils,
and neutrophils [26]. IL-9 relates to survival of T cells and
antibody production from B cells, and also induces IL-6
secretion from bone marrow-derived mast cells. However,
the pathologic role of IL-9 in RA is unknown.
Elevation of IL-17 in gp130F759 mice [16] may be pro-
duced by IL-17-producing helper T-cells (Th17). STAT3,
IL-2 production in lymph node cells of D/J.gp130F759 mice  (female) by collagen and concanavalin A stimulation Figure 7
IL-2 production in lymph node cells of D/J.gp130F759 
mice (female) by collagen and concanavalin A stimu-
lation. Values are expressed as mean ± standard error of 12 
samples. **P < 0.01 versus non-treated group (Spon) by Stu-
dent's t-test. #P < 0.05, ## P < 0.01 versus same condition 
group of wild type mice-derived lymph node cells by Stu-
dent's t-test.
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activated by IL-6 and IL-23, has a critical role in Th17
development [16,27]. CIA is reported to be a Th17-
dependent autoimmune disease [28]. The development of
Th17 in gp130F759 mice may, therefore, contribute to
augmentation of the inflammatory response in CIA.
MIP-1β is a member of the CC chemokine subfamily, and
has been shown to signal mainly through CCR5 [29]. It
has been demonstrated that monocytes produce high
amounts of MIP-1β when stimulated with IL-7 [30]. We
reported that autoimmune disease in gp130 mutant mice
is caused by increased homeostatic proliferation of CD4+
T-cells, which is due to elevated production of IL-7 by
non-hematopoietic cells as a result of IL-6 family
cytokine-gp130-STAT3 signaling [14]. The high level of
MIP-1β may therefore be due to elevated production of IL-
7 in the micro-environment, although it could not be
detected in the serum by ELISA. It has been reported that
MIP-1β expression in RA synovial fluid is elevated, and
MIP-1β may participate in the selective recruitment of
CCR5+CXCR3+ T-cells to the inflamed synovium [31]. Bao
Table 4: Methotrexate attenuated CIA in gp130F759 mice (male, histopathological analysis)
Day 42 Vehicle MTX
Grade 24* 22*
Proliferation of the synovial lining cells 0 7 16
10 0
21 2 3
35 3
40 0
Destruction of the articular cartilage/bone 0 6 16
10 0
23 2
31 5 4
40 0
Inflammatory cell infiltration, rich in neutrophils 0 5 15
10 0
24 1
31 1 6
44 0
All data refer to the number of limbs with the finding in the group.
*Total number of limbs in the group
Grade of change: 0, negative; 1, very slight; 2, slight; 3, moderate; 4, severe.
Methotrexate attenuated CIA (a), and delayed the onset of  arthritis (b) in gp130F759 mice (male) Figure 8
Methotrexate attenuated CIA (a), and delayed the 
onset of arthritis (b) in gp130F759 mice (male). Values 
are expressed as mean ± standard error of 11 to 12 animals. 
*P < 0.05, **P < 0.01 versus vehicle-treated group by Stu-
dent's t-test. aP < 0.05, aaP < 0.01 versus Non-immunized 
group by Student's t-test.
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Methotrexate attenuated the increase of COMP levels (a)  and anti-collagen antibody levels (b) in the serum on day 42 Figure 9
Methotrexate attenuated the increase of COMP lev-
els (a) and anti-collagen antibody levels (b) in the 
serum on day 42. Values are expressed as mean ± standard 
error of 11 to 12 animals. *P < 0.05, **P < 0.01 versus vehi-
cle-treated group by Student's t-test. aaP < 0.01 versus Non-
immunized group (NI) by Student's t-test.
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et al. [32] reported that CCR5 knockout mice show a sig-
nificant reduction in the prevalence of CIA after collagen-
immunization as compared with wild-type mice. Elevated
MIP-1β in gp130F759 mice may partially contribute to
arthritis.
RF and anti-DNA antibody levels were higher in
gp130F759 mice, but anti-type II collagen antibody level
was slightly lower. IL-2 production in lymph node cells of
collagen-immunized D/J.gp130F759 mice stimulated by
collagen was slightly higher than that of the control mice.
These results suggest that immune reactions in
gp130F759 mice and the control mice against heterolo-
gous collagen have slightly different properties. However,
antigen-specific immune responses were not as highly
augmented in gp130F759 from the present data. There-
fore, the augmentation of arthritis in gp130F759 mice
may be due to the increased response of inflammation or
innate immunity. Further studies to clarify the relation
between the augmentation of arthritis in gp130F759 mice
and the humoral or cellular immunity need to be con-
ducted in the future.
We investigated the effects of MTX, which is widely used
for RA treatment, on this model. It has been reported that
MTX ameliorates T-cell-dependent autoimmune arthritis
(including CIA), but not antibody- or fibroblast-induced
arthritis [33]. In CIA in D/J.gp130F759 mice, MTX atten-
uated arthritis development and inhibited bone destruc-
tion. MTX also attenuated elevation of anti-type II
collagen antibody. Svensson et al. [34] reported that B-
cell-deficient mice did not develop CIA. Attenuation of
anti-type II collagen antibody level may, therefore, be one
of the mechanisms for the efficacy of MTX on CIA in D/
J.gp130F759 mice. It is intriguing that MTX attenuated
arthritis with reduction of anti-type II collagen antibody,
which is not enhanced in D/J.gp130F759 mice. We could
not detect significant decreases in the serum level of anti-
ssDNA antibody, RF, MIP-1β, TNF-α, IL-6, IL-9, IL-17, and
IFN-γ in the MTX-treated group at the end of the experi-
mental period, but all factors tended to decrease in the
MTX-treated group. It has been reported that MTX modu-
lates cytokine production by T-cells and macrophages in
murine CIA [35]. The immunosuppressive mechanism of
MTX by cytokine modulation may be important for its
clinical usefulness. We therefore consider that CIA in D/
J.gp130F759 mice in a 2-week interval immunization pro-
tocol is useful for drug evaluation in a relatively short
period because sustained activation of STAT3 may
enhance the disease symptoms. Recently, JAK1/2 inhibi-
tor acting on IL-6-induced STAT3 phosphorylation dem-
onstrated clinical activity in RA [36]. Genetic factors
contribute to the anti-inflammatory efficacy of MTX, and
DBA/1J mice are resistant to MTX [37]. Further studies
may be needed to clarify the similarity between CIA in D/
J.gp130F759 and RA.
Conclusion
The point mutation of Tyr-759 of the IL-6 family cytokine
receptor subunit, gp130, causes autoimmune disease, and
this is also influenced by the genetic background. CIA in
D/J.gp130F759 is useful for evaluating drugs in a rela-
tively short period because sustained activation of STAT3
may enhance the disease symptoms.
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